BIOMARKER PADA KANKER STEM SEL: LITERATURE REVIEW

Authors

  • Emma Ismawatie Politeknik Indonusa Surakarta
  • Inas Hasna Azizah Politeknik Indonusa Surakarta
  • Yulita Maulani Politeknik Indonusa Surakarta

DOI:

https://doi.org/10.47701/sikenas.vi.2851

Keywords:

cancel stem cell, marker, target, terapi

Abstract

Sel punca kanker adalah sel tumor pemicu kanker. CSC terjadi karena kegagalan asimetris pada sel punca yang memicu tumorigenesis. CSC terkait dengan metastasis, perkembangan kanker dan resistensi terhadap terapi. Jalur pensinyalan terkait penanda terlibat dalam kejadian dan perkembangan tumor, dan memiliki dampak signifikan pada proliferasi, metastasis, dan invasi sel kanker, yang dapat digunakan sebagai target terapi molekuler yang potensial. Artikel ini akan membahas penanda pada Cancer Stem Cells. Makalah ini bertujuan untuk menemukan penanda sebagai target terapi di CSC.

References

Artini, I. G. A. 2015. Cancer Stem Cell-Targeted Therapy: Harapan Baru Terapi Kanker. Indonesian Journal of Cancer. DOI: 10.14414/ijoc.v9i3.389

Biehl, Jesse K, and Brenda Russell. 2019. “Introduction to stem cell therapy.” The Journal of cardiovascular nursing vol. 24,2. 98-103; quiz 104-5. doi:10.1097/JCN.0b013e318197a6a5

Chan, M. M., Chen, R., & Fong, D. 2018. Targeting cancer stem cells with dietary phytochemical - Repositioned drug combinations. Cancer letters, 433, 53–64. https://doi.org/10.1016/j.canlet.2018.06.034

DeSano JT, Xu L. 2009. MicroRNA regulation of cancer stem cells and therapeutic implications. AAPS J. 11:682–692.

Fojo T. 2008. Commentary: novel therapies for cancer: why dirty might be better. Oncology. 13:277–283.

Fong D., Chan M.M. 2013. Dietary phytochemicals target cancer stem cells for cancer chemoprevention. In: Chandra D., editor. Mitochondria as Targets for Phytochemicals in Cancer Prevention and Theraphy. Springer; New York: pp. 85–125.

Kartini, K & Adiwinata, J 2018, 'Sel Punca Kanker (Cancer Stem Cells): Sebuah tinjauan pustaka', Majalah Patologi Indonesia, vol. 27.

Lawson JC, Blatch GL, Edkins AL. 2009. Cancer stem cells in breast cancer and metastasis. Breast Cancer Res Treat.118:241–254

Mencher S.K., Wang L.G. 2005. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue) BMC Clin. Pharmacol. 5 3–6904-5-3.

Noh, K. H., Lee, S., Lee, H., Jeong, A. J., Kim, K. O., Shin, H. M., Kim, h., Park. M., Park, J., et al. 2022. Novel cancer stem cell marker MVP enhances temozolomida-resistance in glioblastoma. Translation oncology 15(1). https://doi.org/10.1016/j.tranon.2021.10125

Rey, I. 2020. Hubungan Ekspresi CD133, LGR5, CD166 Sel Punca Kanker Kolorektal dan CD163 Tumor Associated Macrophage Dengan Perbedaan Lokasi Kanker Kolorektal. Fakultas Kedokteran, Univ Sumatera Utara (Skripsi)

Rosen JM, Jordan CT. 2009. The increasing complexity of the cancer stem cell paradigm. Science. 324:1670–1673 Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126:663–676.

Xia, P. Liu, D. 2022. Cancer stem cell markers for liver cancer and pancreatic cancer. Stem Cell Research Vol 60. https://doi.org/10.1016/j.scr.2022.102701

Yu Z, Pestell TG, Lisanti MP, Pestell RG. 2012. Cancer stem cells. Int J Biochem Cell Biol. 2012 Dec;44(12):2144-51. doi: 10.1016/j.biocel.2012.08.022. Epub Sep 2. PMID: 22981632; PMCID: PMC3496019.

Yusuf M, Indra I, Juniati SH, Afriani Dewi Y. 2021. Correlation between CD44+ cancer stem cell expression and histopathological types of nasopharyngeal carcinoma. F1000Res. Nov 3;10:678. doi: 10.12688/f1000research.53643.2. PMCID: PMC8581592.

Zakrzewski, W., Dobrzyński, M., Szymonowicz, M. et al. 2019. Stem cells: past, present, and future. Stem Cell Res Ther 10, 68. https://doi.org/10.1186/s13287-019-1165-

Downloads

Published

2023-06-30

Issue

Section

Articles